OptimizeRx Corp
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $109.4M | $92.1M | $71.5M | $62.5M | $61.3M |
| Cost of revenue | $35.8M | $32.7M | $28.6M | $23.5M | $25.7M |
| Gross profit | $73.6M | $59.4M | $42.9M | $39.0M | $35.6M |
| Selling, general & administrative | — | — | — | $33.5M | $27.7M |
| Research and development | $0 | $0 | — | — | — |
| Operating expenses | $61.9M | $73.1M | $69.3M | $51.3M | $35.3M |
| Operating income | $11.7M | -$13.7M | -$26.4M | -$12.3M | $361,100 |
| Interest expense | $5.3M | $6.2M | $1.5M | — | — |
| Pretax income | $7.0M | -$19.4M | -$25.2M | -$11.4M | $378,079 |
| Income tax expense | $1.8M | $725,000 | -$7.6M | — | — |
| Net income | $5.1M | -$20.1M | -$17.6M | -$11.4M | $378,079 |
| Balance Sheet | |||||
| Cash and equivalents | $23.4M | $13.4M | $13.9M | $18.2M | $84.7M |
| Current assets | $64.7M | $54.0M | $54.3M | $98.6M | $115.1M |
| Total assets | $176.9M | $171.2M | $183.4M | $134.7M | $141.0M |
| Current liabilities | $21.3M | $18.7M | $17.9M | $8.4M | $9.4M |
| Total liabilities | $48.6M | $54.2M | $56.8M | $8.5M | $9.6M |
| Stockholders' equity | $128.3M | $117.0M | $126.6M | $126.1M | $131.4M |
| Cash Flow Statement | |||||
| Cash from operations | $18.7M | $4.9M | -$7.2M | $10.7M | $726,039 |
| Depreciation and amortization | $102,000 | $111,000 | $2.4M | $2.0M | $2.0M |
| Stock-based compensation | $7.0M | $11.5M | $13.7M | $15.7M | $5.5M |
| Capital expenditure | $58,000 | $112,000 | $87,000 | $81,005 | $100,322 |
| Free cash flow | $18.7M | $4.8M | -$7.3M | $10.6M | $625,717 |
| Share repurchases | — | — | $7.5M | $20.0M | — |
| Impairments | $368,000 | $7.5M | $6.7M | — | — |
Shares outstanding 18.8M · Free float 67.1%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.